Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ZW49 |
Synonyms | |
Therapy Description |
ZW49 is an antibody-drug conjugate (ADC) comprising a bispecific ERBB2 (HER2) antibody linked to auristatin, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing cells, potentially resulting in cell growth inhibition and tumor regression (Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-13). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZW49 | ZW-49|ADC ZW49 | HER2 (ERBB2) Antibody 76 HER2 (ERBB2) Antibody-Drug Conjugate 31 | ZW49 is an antibody-drug conjugate (ADC) comprising a bispecific ERBB2 (HER2) antibody linked to auristatin, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing cells, potentially resulting in cell growth inhibition and tumor regression (Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-13). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03821233 | Phase I | ZW49 | A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers | Active, not recruiting | USA | CAN | AUS | 1 |